Put Options

9 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.72 - $8.0 $15,996 - $74,400
-9,300 Reduced 30.0%
21,700 $40,000
Q2 2024

Aug 14, 2024

SELL
$6.56 - $9.89 $26,896 - $40,549
-4,100 Reduced 11.68%
31,000 $229,000
Q1 2024

May 15, 2024

SELL
$5.0 - $9.2 $5,000 - $9,200
-1,000 Reduced 2.77%
35,100 $274,000
Q4 2023

Feb 14, 2024

SELL
$4.02 - $6.08 $81,203 - $122,816
-20,200 Reduced 35.88%
36,100 $183,000
Q3 2023

Nov 14, 2023

SELL
$5.91 - $7.37 $82,149 - $102,443
-13,900 Reduced 19.8%
56,300 $333,000
Q2 2023

Aug 14, 2023

SELL
$7.15 - $9.39 $36,465 - $47,889
-5,100 Reduced 6.77%
70,200 $520,000
Q1 2023

May 15, 2023

BUY
$8.51 - $14.26 $106,375 - $178,250
12,500 Added 19.9%
75,300 $711,000
Q4 2022

Feb 14, 2023

BUY
$7.05 - $14.41 $167,085 - $341,517
23,700 Added 60.61%
62,800 $668,000
Q3 2022

Nov 14, 2022

SELL
$4.81 - $8.48 $4,810 - $8,480
-1,000 Reduced 2.49%
39,100 $289,000

Others Institutions Holding ATNM

About Actinium Pharmaceuticals, Inc.


  • Ticker ATNM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,184,700
  • Market Cap $32.5M
  • Description
  • Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...
More about ATNM
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.